GLP-1 + PYY3-36

GLP-1 + PYY3-36 is an investigational combination therapy consisting of two gut-derived peptide hormones, glucagon-like peptide 1 (GLP-1) and peptide YY in its active form (PYY3–36). Both peptides are secreted postprandially from intestinal L-cells and play key roles in appetite regulation and energy homeostasis. GLP-1 acts as an incretin hormone, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite via central mechanisms. PYY3–36 primarily acts through the neuropeptide Y2 receptor (Y2-R) in the hypothalamus to promote satiety and reduce food intake. When administered together by infusion or as co-formulated agonists, these peptides demonstrate synergistic effects on reducing energy intake beyond either monotherapy. The combination has been shown to significantly decrease ad libitum food consumption in overweight individuals compared to placebo or single agents[1][2]. Preclinical studies suggest that this dual approach may also enhance weight loss more effectively than monotherapy with a GLP-1 receptor agonist[4]. The main therapeutic targets are obesity/weight management and potentially type 2 diabetes mellitus due to their combined effects on appetite suppression and glucose metabolism[2][4]. No approved pharmaceutical product currently exists under this exact formulation; development is ongoing.

Other names

glucagon-like peptide 1 + peptide YY3-36GLP-1 7–36 amide + PYY 3–36